Cathy Kelly
Senior editor
Washington DC, USA
42+ years of experience
Pink Sheet
By Cathy Kelly 18 Nov 2020
Regardless of the outcomes of the US elections, drug pricing is likely to take a back seat to COVID as policy focus. But the pandemic does offer pharma an opportunity for partnerships with payers on health outcomes. Commonwealth Fund’s Liz Fowler, South Capitol’s John O’Brien and ICER’s Steve Pearson discuss where drug pricing stands in public opinion, whether policies embraced by President Trump will have staying power, and the conditions needed in the policy environment for major change.
Pink Sheet
By Cathy Kelly 09 Aug 2019
Investigation may help define when rebate arrangements seeking to protect a brand against biosimilar competition are anticompetitive.
Topic Policy & Regulation
Scrip
By Cathy Kelly 19 Nov 2018
Mylan’s Symfi and Merck’s Zepatier gain preferred status on PBM's national preferred formulary for 2019. But more drugs are excluded from coverage – 242, up from 196 in 2018.
Pink Sheet
By Cathy Kelly 26 Sep 2018
Approach has been endorsed by Express Scripts as more workable solution than trying to cut list prices for drugs already on the market.
Pink Sheet
By Cathy Kelly 21 Sep 2018
Even though measure was blocked in Congress, it may still advance through regulation.
Pink Sheet
By Cathy Kelly 22 Aug 2018
Regulations allow manufacturers to request that drug production and marketing costs and price contracting information provided to the state be kept confidential.
Topic Approvals
Pink Sheet
By Cathy Kelly 22 Aug 2018
Companies should introduce same drug under new NDC at lower list price to overcome difficulties of reducing list prices on existing brands, PBM says.
Topic Policy & Regulation
Pink Sheet
By Cathy Kelly 06 Jun 2018
HHS Office of Inspector General traces reimbursement, pricing, rebating and utilization patterns for established brands from 2011 to 2015.
Pink Sheet
By Cathy Kelly 18 May 2018
Medicare begins analysis process for CAR-T cancer therapies in response to a request from United Healthcare for a national coverage policy.
Topic Cancer Cell & Gene Therapy
Pink Sheet
By Cathy Kelly 27 Jan 2018
Alex Azar's nomination clears Senate with support from five Democrats and one Independent.
Pink Sheet
By Cathy Kelly 16 Nov 2017
Concerns with promoting competition and reducing consumers' 'pain in the pocketbook' are key tenets of the Trump Administration's approach.
Topic Reimbursement
Pink Sheet
By Cathy Kelly 23 Sep 2017
'We have about 18 different projects underway but we've achieved'
Pink Sheet
By Cathy Kelly 15 Sep 2017
Biopharma manufacturers, payers and other stakeholders strongly support changing an Obama-era policy for reimbursing biosimilars.
Topic Biosimilars
Pink Sheet
By Cathy Kelly 31 Aug 2017
The Centers for Medicare and Medicaid Services will only pay for Kymriah if patients respond after one month.
Topic Reimbursement
Pink Sheet
By Cathy Kelly 09 Aug 2017
Four contracts test approaches tying reimbursement to relapse rates and discontinuation of treatment.
Topic Reimbursement
Pink Sheet
05 Jul 2022
Pink Sheet
05 Jul 2022
Pink Sheet
29 Jun 2022
Pink Sheet
22 Jun 2022
Pink Sheet
06 Jun 2022
Pink Sheet
01 Jun 2022
Pink Sheet
06 May 2022
Pink Sheet
04 May 2022
HBW Insight
25 Apr 2022
Medtech Insight
25 Apr 2022
Pink Sheet
15 Apr 2022
Pink Sheet
13 Apr 2022
Pink Sheet
30 Mar 2022
Pink Sheet
25 Mar 2022
Pink Sheet
14 Mar 2022